KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Operating Expenses: 2012-2024

Historic Other Operating Expenses for Xenon Pharmaceuticals (XENE) over the last 6 years, with Dec 2024 value amounting to -$20.7 million.

  • Xenon Pharmaceuticals' Other Operating Expenses fell 47.36% to -$6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.8 million, marking a year-over-year decrease of 161.13%. This contributed to the annual value of -$20.7 million for FY2024, which is 43.69% down from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Other Operating Expenses is -$20.7 million, which was down 43.69% from -$14.4 million recorded in FY2023.
  • Xenon Pharmaceuticals' Other Operating Expenses' 5-year high stood at -$10.0 million during FY2022, with a 5-year trough of -$20.7 million in FY2024.
  • Moreover, its 3-year median value for Other Operating Expenses was -$14.4 million (2023), whereas its average is -$15.0 million.
  • Data for Xenon Pharmaceuticals' Other Operating Expenses shows a maximum YoY slumped of 43.82% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Xenon Pharmaceuticals' Other Operating Expenses stood at -$10.0 million in 2022, then slumped by 43.82% to -$14.4 million in 2023, then slumped by 43.69% to -$20.7 million in 2024.